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Abstract
A large body of evidence links a high dietary intake of n–3 (v-3) polyunsaturated fatty acids (PUFAs) with improved
cardiometabolic outcomes. Recent studies suggested that the biologic processes underlying the observed associations
may involve epigenetic changes, specifically DNA methylation. To evaluate changes in methylation associated with n–3
PUFA intake, we conducted an epigenome-wide methylation association study of long-chain n–3 PUFA intake and tested
associations between the diabetes- and cardiovascular disease–related traits.We assessed DNAmethylation at;470,000
cytosine–phosphate–guanine (CpG) sites in a cross-sectional study of 185 Yupik Alaska Native individuals representing
the top and bottom deciles of PUFA intake. Linear regression models were used to test for the associations of interest,
adjusting for age, sex, and community group. We identified 27 differentially methylated CpG sites at biologically relevant
regions that reached epigenome-wide significance (P < 1 3 1027). Specifically, regions on chromosomes 3 (helicase-like
transcription factor), 10 (actin a 2 smooth muscle/Fas cell surface death receptor), and 16 (protease serine 36/C16 open
reading frame 67) each harbored 2 significant correlates of n–3 PUFA intake. In conclusion, we present promising evidence
of association between several biologically relevant epigenetic markers and long-term intake of marine-derived n–3
PUFAs. J. Nutr. 144: 425–430, 2014.
Introduction
Dietary n–3 PUFAs, specifically fish- and marine mammal–derived
EPA and DHA, are inversely associated with the risk of cardio-
vascular disease (1). At very high intakes, such as the ones observed
in Arctic populations, EPA and DHA are not only associated
with improved dyslipidemia and reduced chronic inflammation
(2) but also attenuate the effects of elevated BMI on markers of
cardiometabolic dysfunction, such as elevated TGs of C-reactive
protein (3). The underlying biologic mechanisms are incompletely
understood but are thought to include altered eicosanoid metab-
olism and subsequent changes in cell signaling, transcription
factor activity, and gene expression (4). An emerging body of
evidence in animal models suggests that long-chain n–3 PUFAs
may also influence global DNA methylation patterns because of
their role in one-carbon metabolism (5). Such epigenetic changes
likely contribute to the observed n–3 PUFA effects on gene expres-
sion, dyslipidemia, and inflammation and warrant additional inves-
tigation in the context of chronic disease.
To evaluate the contributions of dietary long-chain n–3 PUFAs
to DNA methylation across the human genome, we analyzed
data from a population-based sample of the Yupik people living
in Southwest Alaska. Because of the traditional diet rich in fish
and other marine foods, our study population has mean intakes
of EPA and DHA that surpass mean intakes of the general U.S.
population by >20-fold (6–8), offering an unprecedented oppor-
tunity to investigate connections between dietary PUFAs, DNA
methylation patterns, and known markers of disease. In this
epigenome-wide study of EPA and DHA biomarkers, we set out
to identify genomic regions in which DNA methylation is cor-
related with habitual intake of long-chain marine n–3 PUFAs. In
turn, we hypothesized that such differentially methylated geno-
mic regions are associated with intermediate phenotypes, such as
plasma lipids or inflammatory cytokines, presenting a compre-
hensive nutrigenomic paradigm of protection from chronic disease.
Participants and Methods
Participant recruitment and ethics. Since 2003, the Center for Alaska
Native Health Research has recruited 1518 participants aged $14 y in
11 Southwest Alaska communities to investigate obesity and chronic
disease risk factors in the Yupik people. Details on participant recruit-
ment and procedures can be found in previous Center for Alaska Native
Health Research publications (9,10). Briefly, all community residents are
invited to participate, and the age distribution reflects that of all eligible
participants as shown by the 2000 U.S. census data. Participants provided
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2 Author disclosures: S. Aslibekyan, H. W. Wiener, P. J. Havel, K. L. Stanhope,
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3 Supplemental Figures 1 and 2 are available from the ‘‘Online Supporting
Material’’ link in the online posting of the article and from the same link in the
online table of contents at http://jn.nutrition.org.
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Supplemental Material can be found at:
written informed consent using protocols approved by the University of
Alaska Institutional Review Board, the National and Alaska Area Indian
Health Service Institutional Review Boards, and the Yukon Kuskokwim
Human Studies Committee.
Study sample. From the 1518 participants of the main study, 1499 had
available biomarker data on n–3 PUFA intake, measured using the
nitrogen stable isotope ratio (d15N)10 as described below. Of those, 450
were in the bottom 3 deciles of PUFA intake, whereas 446 were in the top
3 deciles. We chose individuals from the top 3 deciles and the bottom 3
deciles of the d15N intake distribution to represent traditional Yupik and
modern U.S. dietary patterns, respectively. This ‘‘extreme phenotypes’’
approach had the additional benefit of increasing statistical power (11).
All participants consented to participate in the convenience sample
for the epigenetic analyses. Of all individuals in the top 3 and the bottom
3 deciles of PUFA intake, we selected 192 unrelated participants for the
methylation assay based on their d15N decile and age. We excluded in-
dividuals if they were in the lowest decile of age (<21 y), not of Yupik
descent, or lacked information on clinical covariates. Of 192 individuals
selected for the epigenetic study, methylation was successfully measured
on 185. Of these 185 individuals, 93 were in the lowest 3 deciles of n–3
PUFA intake (32, 42, and 19 for deciles 1, 2, and 3, respectively), and 92
were in the top 3 (30, 38, and 24 in deciles 8, 9, and 10, respectively). More
than 98% of the 185 individuals were unrelated, and <1%were closer than
4th-degree relatives. Given the small sample size and the sparseness of
relations, we did not correct our analyses for familial correlation.
Anthropometric and clinical measurements. Anthropometric mea-
surements, which included height, weight, percentage body fat, and waist
circumference, were obtained using the NHANES III Anthropometric
Procedures Manual (12). Participants fasted overnight before collecting
blood samples. We quantified metabolic traits, including plasma lipopro-
teins, fasting insulin and glucose, and glycosylated hemoglobin (HbA1c),
as described in previous publications from our group (13–15).
n–3 PUFA measurements. We assessed dietary intake of marine-
derived long-chain n–3 PUFAs using the d15N of RBCs as described
previously (14,15). The life of an RBC is ;120 d; therefore, we can use
this validated biomarker to objectively measure moderately long-term
n–3 PUFA intake in our study population. Conventionally, d15N are
expressed in per mil (&) abundance of 15N relative to atmospheric
nitrogen (15N/14Natm = 0.0036765) and calculated using the following
equation:
d15N = [(15N/14Nsample 2
15N/14Natm)/(
15N/14Natm)] 3 1000&.
We tested analytical accuracy and precision by running laboratory
reference materials (peptone, d15N = 7.00); the resulting d15N estimate
was 7.06 0.2& (mean6 SD). The range of isotopic variation in the data
(9&) was very large relative to analytical precision (0.2&) (15).
DNA methylation measurements. We quantified DNA methylation
using the Infinium Human Methylation 450 array (Illumina, San Diego,
CA). DNAwas isolated using Puregene Blood Kits (Qiagen, Venlo, The
Netherlands). Before the standard manufacturer protocol of ampli-
fication, hybridization, and imaging, we treated 500 ng of each DNA
sample with sodium bisulfite (Zymo Research, Irvine, CA) (16). We used
Illumina GenomeStudio software to estimate b scores, defined as the
proportion of total signal from the methylation-specific probe or color
channel, and detection P values, defined as the probability that the total
intensity for a given probe falls within the background signal intensity.
After measuring methylation on ;470,000 autosomal cytosine–phos-
phate–guanine (CpG) sites, we removed any individual b scores with a
detection P value > 0.01, all data from CpGs in which >10% of samples
failed to yield adequate intensity, and all data from samples with >1.5%
missing data points (16). Finally, we identified any CpGs in which the
probe sequence mapped to either a location that did not match the
annotation file or >1 locus and eliminated these markers from the analysis.
Statistical analyses. All linear models that were fit included as covar-
iates sex, age, and community group. The community group is a dichot-
omous variable that indicates proximity of the community to the coast as
described previously (15). In addition, we included the microarray iden-
tification number (each array assays 12 samples) to account for possible
batch effects at each CpG. Initial models used the logit-transformed
methylation values similar to M-values as outcome variables (17) and
included d15N as a predictor and covariates described above to determine
which loci were significantly associated with PUFA intake.
Additionally, the logit-transformed methylation values for significant
loci obtained from the analysis above were then corrected for methylation
principal components and batch effects in a linearmodel, and the residuals
of these models were used as predictors in models for cardiovascular
disease– and diabetes-related traits. We implemented stringent Bonferronis
corrections to adjust for multiple testing, with the significance level set at
0.05/470,000 = 1.1 3 1027 for the n–3 PUFA analyses and 0.05/27 =
0.002 for the chronic disease marker analyses.
Results
Demographic and clinical characteristics of the study popula-
tion, stratified by intake of n–3 FAs, are summarized in Table 1.
Community group was the strongest correlate of n–3 PUFA
intake: compared with the inland communities, the coastal vil-
lages were more likely to be in the high d15N group. Age and sex
also exhibited statistically significant relations with marine-
derived PUFA intake, with older individuals and women more
likely to consume an n–3 PUFA-rich diet, although individuals in
the high n–3 PUFA intake group had a marginally higher (P =
0.06) body fat percentage that did not translate to a difference in
BMI, HbA1c, or fasting glucose. Individuals at the higher end of
the d15N distribution showed lower plasma TGs (P = 0.02) and
higher HDL cholesterol (P = 0.003) concentrations but also
borderline higher LDL (P = 0.07) and total (P = 0.06) cholesterol
TABLE 1 Demographic and clinical characteristics of the study
sample by n–3 FA intake (n = 185)1
High d15N
(n = 92)
Low d15N
(n = 93)
P
value
Age, y 40 6 1 36 6 1 0.009
Community group, n (%) 4 3 10212
Coastal 74 (80) 28 (30)
Upriver 28 (20) 65 (70)
Male, n (%) 37 (40) 54 (58) 0.02
Current tobacco users, n (%) 78 (85) 77 (83) 0.84
BMI,2 kg/m2 28 6 1 28 6 1 0.57
Body fat, % 30 6 2 27 6 2 0.06
Plasma TGs,3 mg/dL 77 6 4 103 6 11 0.02
Plasma LDL cholesterol, mg/dL 146 6 4 136 6 4 0.07
Plasma HDL cholesterol,2 mg/dL 65 6 2 58 6 2 0.003
Plasma total cholesterol, mg/dL 227 6 4 214 6 5 0.06
Plasma fasting glucose,3 mg/dL 95 6 1 93 6 1 0.22
Plasma glycosylated hemoglobin,3 % 5.48 6 0.03 5.45 6 0.04 0.52
1 All values are means 6 SEs or n (%). d15N, nitrogen stable isotope ratio.
2 The variable was logit-transformed to achieve normality.
3 The variable underwent a Box-Cox transformation to achieve normality.
10 Abbreviations used: ABCG8, ATP-binding cassette subfamily G member 8;
ACTA2, actin a 2 smooth muscle; AHRR, aryl-hydrocarbon receptor repressor;
APOB, apolipoprotein B; ASXL2, additional sex combs-like 2; C16orf67, C16 open
reading frame 67;CCL17, chemokine ligand 17; CpG, cytosine–phosphate–guanine;
FAS, Fas cell surface death receptor; HbA1c, glycosylated hemoglobin; HLTF,
helicase-like transcription factor; INADL, gene encoding the inactivation no
afterpotential D-like protein;NAV1, neuron navigator 1;PRSS36, protease serine 36;
d15 N, nitrogen stable isotope ratio.
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concentrations compared with individuals in the bottom 3
deciles of d15N.
The results from the epigenome-wide analysis of d15N are
illustrated by the Manhattan plot in Supplemental Fig. 1. Of
;470,000 autosomal markers that were tested, 27 have reached
the Bonferronis threshold for epigenome-wide significance and
are listed in Table 2. Despite the limited sample size, our findings
show robust statistical significance, with P < 1 3 10210 for 10
markers. Regions that harbored >1 statistically significant CpG
were located on chromosomes 3 [helicase-like transcription fac-
tor (HLTF)], 10 [actin a 2 smooth muscle/Fas cell surface death
receptor (ACTA2/FAS)], and 16 [protease serine 36 (PRSS36)/C16
open reading frame 67 (C16orf67)]. Interestingly, the direction
of association within these 3 genomic regions was concordant
across CpG sites, with n–3 PUFA intake mostly associated with
increased methylation (78% of significant associations) (Table
2). Deviations from the expected distribution were assessed
using a quantile–quantile plot (Supplemental Fig. 2). Sensitivity
analyses that included information on tobacco use, an estab-
lished predictor of methylation status, did not yield substantially
different results.
We then tested for associations between the 27 CpG sites that
emerged as the statistically significant correlates of d15N and a
number of chronic disease risk factors, shown in Table 3. After
adjusting for multiple testing, none of these associations reached
statistical significance. However, a CpG in the aryl-hydrocarbon
receptor repressor (AHRR) was suggestively negatively associ-
ated with fasting glucose (P = 0.004), and CpGs in the ACTA2/
FAS and additional sex combs-like 2 (ASXL2) loci reached or
approached nominal significance for LDL cholesterol (P = 0.07,
0.01, and 0.01, respectively) (Table 3). Specifically, the methyl-
ation status of both CpGs in ACTA2/FAS was positively asso-
ciated with the lipid concentrations, whereas methylation of a
CpG site in ASXL2 had an inverse association (Table 3). Addi-
tional adjustment for d15N strengthened the associations with
the methylation of ACTA2/FAS CpGs (P = 0.01 and 0.06), de-
creased the association between AHRR methylation and fasting
glucose (P = 0.009), and did not appreciably alter the association
between ASXL2 methylation and LDL cholesterol (P = 0.01);
however, after implementing the Bonferronis correction, none
of the d15N-adjusted associations were significant (Table 3).
Discussion
We present an epigenome-wide association study of n–3 PUFA
intake, conducted in a Yupik population characterized by unique
dietary PUFA variability. Our study links DNA methylation
TABLE 2 Top cytosine–phosphate–guanine methylation sites associated with n–3 PUFA intake in the
study population (n = 185)1
Chromosome Position Marker Gene
Genomic
region
Direction of
association P
1 201,625,499 cg07999988 NAV1 — + ,1 3 10216
16 57,437,864 cg02050165 CCL17 — + 8 3 10216
10 124,905,105 cg05144067 — North Shore 2 5 3 10215
3 148,804,275 cg21926402 HLTF Island 2 2 3 10214
12 133,345,809 cg07249343 GOLGA3 North Shelf + 8 3 10214
1 12,633,465 cg05230551 DHRS3 — + 1 3 10212
3 148,804,272 cg04836786 HLTF Island 2 1 3 10211
17 29,159,594 cg05952098 ATAD5 South Shore + 2 3 10211
11 64,794,859 cg17101226 SNX15 Island + 3 3 10211
6 7,313,623 cg00520393 SSR1 Island + 5 3 10211
5 434,998 cg22951524 AHRR — + 1 3 10210
2 171,571,716 cg06272543 SP5/LOC440925 Island 2 2 3 10210
1 182,759,062 cg15293611 — Island + 2 3 10210
15 34,635,452 cg22686731 NOP10 — + 3 3 10210
1 150,601,613 cg23912435 ENSA North Shore + 3 3 1029
10 90,749,255 cg06450397 ACTA2/FAS North Shore + 4 3 1029
2 26,101,348 cg19084174 ASXL2 Island + 5 3 1029
3 148,804,477 cg24041269 HLTF Island 2 1 3 1028
16 31,711,872 cg16585380 C16orf67 Island + 1 3 1028
15 40,226,279 cg21830797 EIF2AK4 Island + 2 3 1028
9 13,284,899 cg21186560 — — + 2 3 1028
20 331,827 cg24601011 NRSN2 South Shelf 2 4 3 1028
10 90,750,580 cg03672854 ACTA2/FAS Island + 5 3 1028
6 21,666,569 cg10086104 FLJ22536 North Shore + 6 3 1028
3 51,705,097 cg03855276 TEX264 Island + 6 3 1028
1 43,855,450 cg05704639 C1orf84/MED8 Island + 6 3 1028
16 31,153,871 cg07065683 PRSS36 Island + 8 3 1028
1 ACTA2, actin a 2 smooth muscle; AHRR, aryl-hydrocarbon receptor repressor; ASXL2, additional sex combs-like 2; ATAD5, ATPase family
AAA domain containing 5; C16orf67, C16 open reading frame 67; C1orf84, C1 open reading frame 84; CCL17, chemokine ligand 17; DHRS3,
dehydrogenase/reductase SDR family member 3; EIF2AK4, eukaryotic translation initiation factor 2 a kinase 4; ENSA, endosulfine a;
FAS, Fas cell surface death receptor; FLJ22536, hypothetical locus LOC401237; GOLGA3, golgin A3; HLTF, helicase-like transcription factor;
LOC440925, uncharacterized LOC440925;MED8, mediator complex subunit 8; NAV1, neuron navigator 1; NOP10, NOP10 ribonucleoprotein;
NRSN2, neurensin 2; PRSS36, protease serine 36; SNX15, sorting nexin 15; SP5, SP5 transcription factor; SSR1, signal sequence receptor a;
TEX264, testis expressed 264; —, not available.
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patterns in several genomic regions to n–3 PUFA intake, as well
as fasting plasma glucose and LDL cholesterol. Thus, we provide
preliminary evidence in support of the emerging hypothesis of
nutritional regulation of epigenetic changes that may be in-
volved in protection from metabolic and cardiovascular disease.
The identified CpG sites in or near neuron navigator 1 (NAV1),
chemokine ligand 17 (CCL17), ACTA2/FAS, and AHRR are of
particular biologic salience. The CpG site with the strongest
association to d15N is located proximally to a gene encoding the
inactivation no afterpotential D-like protein (INADL) and
contains a genetic variant estimated previously to explain 3% of
the variance in body weight and body composition in Hispanic
children (18). However, in our sample, the methylation of that
site was not associated with BMI, body fat percentage (results
not shown), or any other chronic disease marker, potentially
suggesting actions of yet unknown compensatory mechanisms
and warranting future investigation. The second most robustly
associated CpG site is located in CCL17, which encodes a che-
mokine pivotal to regulating T-cell homeostasis that had been
linked to atherosclerosis and other inflammatory conditions (19).
Two studies of infants whose mothers were administered n–3
PUFA supplementation during pregnancy (20,21) found that
long-chain PUFAs reduce plasma Ccl17, attenuating the inflam-
matory response and providing a plausible biologic mechanism
for our observed association. However, it is worth noting that
the observed associations between CCL17 methylation and d15N
also did not translate into changes in chronic disease risk factors,
possibly because of the limited sample size. In light of these
findings and other studies from our group (3), future investiga-
tions in larger cohorts should consider including measures of
C-reactive protein or other inflammatory cytokines to further
elucidate the interplay between n–3 PUFA intake and CCL17
methylation in human health.
Two markers in the ACTA2/FAS cluster were significantly cor-
related with d15N (P = 4 3 1029 and 5 3 1028) and suggestively
associated with LDL cholesterol (P = 0.01 and 0.07). FAS is
crucial to controlling apoptosis in the immune system. The Fas
death receptor is expressed on T-cells within atherosclerotic lesions;
in mice, Fas deficiency has been shown to promote systemic in-
flammation (22). A polymorphism located in the FAS promoter
region has been linked to lipodystrophy in the context of HIV
(23). It is possible that DNA methylation in that region, perhaps
in concert with sequence variations, reduces FAS expression and
regulates lipid metabolism through the apoptotic pathway. Future
investigations may consider integrating genetic, epigenetic, and
transcriptional data to further disentangle the observed relation.
Another finding of biologic interest emerged from a CpG site
in AHRR, the differential methylation and expression of which
TABLE 3 Associations between epigenetic correlates of n–3 PUFA intake and selected disease-related traits (n = 185)1
HDL cholesterol LDL cholesterol Total cholesterol TGs HbA1c Fasting glucose
CpG site Gene Adj-P2 P3 Adj-P P Adj-P P Adj-P P Adj-P P Adj-P P
cg00520393 SSR1 0.88 0.64 0.32 0.41 0.65 0.76 0.31 0.43 0.91 0.95 0.28 0.21
cg02050165 CCL17 0.36 0.28 0.30 0.35 0.74 0.81 0.73 0.63 0.96 0.98 0.05 0.04
cg03672854 ACTA2/FAS 0.74 0.60 0.01 0.01 0.09 0.10 0.77 0.67 0.57 0.56 0.12 0.09
cg03855276 TEX264 0.66 0.75 0.22 0.25 0.35 0.38 0.72 0.66 0.94 0.94 0.02 0.02
cg04836786 HLTF 0.45 0.62 0.26 0.31 0.40 0.47 0.55 0.67 0.41 0.43 0.83 0.94
cg05144067 — 0.44 0.32 0.33 0.28 0.19 0.16 0.77 0.90 0.49 0.52 0.23 0.18
cg05230551 DHRS3 0.92 0.59 0.67 0.52 0.66 0.53 0.36 0.57 0.99 0.93 0.92 0.72
cg05704639 C1orf84/MED8 0.31 0.24 0.54 0.60 0.88 0.94 0.45 0.38 0.92 0.94 0.09 0.07
cg05952098 ATAD5 0.47 0.30 0.53 0.66 0.67 0.79 0.62 0.48 0.42 0.45 0.41 0.32
cg06272543 SP5/LOC440925 0.44 0.72 0.97 0.88 0.93 0.93 0.08 0.15 0.92 0.88 0.64 0.83
cg06450397 ACTA2/FAS 0.74 0.88 0.06 0.07 0.85 0.90 0.86 0.95 0.65 0.64 0.12 0.10
cg07065683 PRSS36 0.82 0.75 0.43 0.40 0.35 0.33 0.54 0.60 0.20 0.20 0.30 0.29
cg07249343 GOLGA3 0.47 0.31 0.58 0.69 0.95 0.94 0.60 0.47 0.49 0.48 0.09 0.06
cg07999988 NAV1 0.36 0.20 0.27 0.37 0.82 0.96 0.98 0.78 0.31 0.33 0.72 0.89
cg10086104 FLJ22536 0.43 0.56 0.45 0.40 0.48 0.43 0.07 0.10 0.45 0.44 0.91 0.83
cg15293611 — 0.22 0.11 0.67 0.53 0.54 0.43 0.41 0.27 0.66 0.70 0.70 0.92
cg16585380 C16orf67 0.39 0.41 0.34 0.33 0.60 0.59 0.31 0.32 0.72 0.72 0.63 0.61
cg17101226 SNX15 0.60 0.49 0.39 0.45 0.52 0.58 0.37 0.31 0.52 0.54 0.86 0.76
cg19084174 ASXL2 0.28 0.17 0.01 0.01 0.01 0.01 0.61 0.47 0.83 0.85 0.52 0.45
cg21186560 — 0.85 0.66 0.49 0.58 0.50 0.58 0.63 0.52 0.82 0.79 0.23 0.30
cg21830797 EIF2AK4 0.58 0.49 0.66 0.71 0.88 0.93 0.97 0.89 0.64 0.66 0.43 0.38
cg21926402 HLTF 0.49 0.31 0.22 0.30 0.66 0.78 0.96 0.85 0.08 0.09 0.76 0.93
cg22686731 NOP10 0.47 0.35 0.46 0.40 0.22 0.19 0.52 0.63 0.42 0.40 0.09 0.06
cg22951524 AHRR 0.29 0.15 0.23 0.16 0.13 0.09 0.69 0.50 0.98 0.98 0.009 0.004
cg23912435 ENSA 0.20 0.37 0.70 0.58 0.85 0.74 0.39 0.55 0.89 0.92 0.11 0.08
cg24041269 HLTF 0.47 0.68 0.10 0.14 0.26 0.33 0.17 0.24 0.09 0.11 0.88 0.97
cg24601011 NRSN2 0.97 0.65 0.17 0.12 0.16 0.12 0.07 0.14 0.28 0.31 0.44 0.34
1 ACTA2, actin a 2 smooth muscle; Adj, adjusted; AHRR, aryl-hydrocarbon receptor repressor; ASXL2, additional sex combs-like 2; ATAD5, ATPase family AAA domain containing
5; C16orf67, C16 open reading frame 67; C1orf84, C1 open reading frame 84; CCL17, chemokine ligand 17; CpG, cytosine–phosphate–guanine; DHRS3, dehydrogenase/reductase
SDR family member 3; EIF2AK4, eukaryotic translation initiation factor 2 a kinase 4; ENSA, endosulfine a; FAS, Fas cell surface death receptor; FLJ22536, hypothetical locus
LOC401237; GOLGA3, golgin A3; HbA1c, glycosylated hemoglobin; HLTF, helicase-like transcription factor; LOC440925, uncharacterized LOC440925;MED8, mediator complex
subunit 8; NAV1, neuron navigator 1; NOP10, NOP10 ribonucleoprotein; NRSN2, neurensin 2; PRSS36, protease serine 36; SNX15, sorting nexin 15; SP5, SP5 transcription factor;
SSR1, signal sequence receptor a; TEX264, testis expressed 264; —, not available.
2 For all Adj-P columns, correlation adjusted for n–3 PUFA intake.
3 For all P columns, correlation unadjusted for n–3 PUFA intake.
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have been linked recently to smoking status (24). However, our
sensitivity analyses that adjusted for tobacco use (data not shown)
did not appreciably change the estimate of association, suggest-
ing involvement of alternative mechanisms. AHRR encodes the
aryl-hydrocarbon receptor, a pleiotropic protein also implicated
in carcinogenesis and oxidative stress pathways (25). In addition
to its association with n–3 PUFA intake (P = 53 10210), AHRR
methylation was suggestively associated (P = 0.004) with fasting
glucose in our data set. The positive effects of n–3 PUFA intake
on insulin sensitivity and glucose tolerance have been well estab-
lished, including in circumpolar populations (26). Our findings
suggest that the underlyingmechanismsmay involve the oxidative
stress pathway, in particularAHRRmethylation and consequent
changes in expression. Another finding linking carcinogenesis
and n–3 PUFA intake is the differential methylation of 2 markers
inHLTF, a tumor suppressor protein silenced in a variety of digestive
tract cancers (27). Although in our population the methylation
status of 1 of theHLTF sites was only suggestively associated (P =
0.09) with disease markers—particularly HbA1c—further stud-
ies of that region may produce valuable insights into the shared
inflammatory mechanisms relevant to both cancer and meta-
bolic disease.
Finally, we observed an association of the methylation status
of a CpG site in ASXL2 with d15N (P = 5 3 1029), as well as
marginal associations with LDL (P = 0.01) and total (P = 0.01)
cholesterol. ASXL2 is located under the linkage peak for serum
lipid concentrations identified in the Amish Family Study (28),
and the observed association is likely because of the proximity to
well-known lipid loci in apolipoprotein B (APOB) andATP-binding
cassette subfamily G member 8 (ABCG8). Because several stud-
ies, including 1 from our group (29), demonstrated that DNA
methylation status is often influenced by the underlying sequence,
future interrogations of that genomic region may consider genetic
and epigenetic variation jointly to produce a more complete
picture of the association observed in our study population.
The main strengths of this study are the use of a validated
biomarker for EPA and DHA intake, the unparalleled range of
marine-derived n–3 PUFA consumption among the Yupik people,
the epigenome-wide coverage of the methylation array, and the
biologically relevant nature of our most significant findings. Never-
theless, our results must be interpreted in light of several consid-
erations. First, our study is cross-sectional and thus cannot be
used to infer causality, because the temporal order of the relation
between d15N and DNA methylation is yet to be determined.
Second, we do not have genotype or transcription information at
the differentially methylated loci and are thus limited in our
understanding of the underlying biologic mechanisms. Because
our study represents preliminary data, future investigations based
on our findings should include replication in independent pop-
ulations and functional analyses of the top CpG hits and tech-
nical validation of the DNA methylation array in this study
population. Third, because this is an investigation involving only
a small sample of individuals, it is possible that some of the
association findings did not reach statistical significance because
of insufficient statistical power. However, the magnitude of the
observed effects remains impressive despite the limited sample
size, and our findings merit follow-up in larger, well-characterized
cohorts. Fourth, a recent study from our group showed that n–3
PUFA consumption in the Yupik people is part of the larger
subsistence dietary pattern (7,30,31), and thus our observed
associations could be due to confounding by other dietary or
lifestyle variables. Although we have taken careful steps to statisti-
cally account for this possibility, residual confounding remains a
plausible explanation for our findings. Finally, because our study
represents a hypothesis-free research approach, our findings must
be replicated in an independent population to ensure validity.
In conclusion, we conducted an epigenome-wide search for
CpG methylation sites associated with marine-derived EPA and
DHA intake and discovered several biologically relevant regions
with robust associations. By highlighting the most promising
regions of the genome, our study lays the groundwork for future
hypothesis-driven investigations of the role of n–3 PUFAs in
epigenetic processes and metabolic health in human populations.
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